Real-world clinical outcomes of patients with early-stage TNBC and BRCAm who were treated with adjuvant capecitabine in the United States.

Lynce F, Ru M, Luo L, Miranda M, Xu X, Isaacs C.

Open source

DOI
10.1007/s10549-026-08011-6
Published
2026-08-12
Container
Breast Cancer Res Treat
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s10549-026-08011-6,
  title = {Real-world clinical outcomes of patients with early-stage TNBC and BRCAm who were treated with adjuvant capecitabine in the United States.},
  author = {Lynce F and  Ru M and  Luo L and  Miranda M and  Xu X and  Isaacs C.},
  year = {2026},
  journal = {Breast Cancer Res Treat},
  doi = {10.1007/s10549-026-08011-6},
  url = {https://doi.org/10.1007/s10549-026-08011-6}
}

RIS

TY  - JOUR
TI  - Real-world clinical outcomes of patients with early-stage TNBC and BRCAm who were treated with adjuvant capecitabine in the United States.
AU  - Lynce F
AU  -  Ru M
AU  -  Luo L
AU  -  Miranda M
AU  -  Xu X
AU  -  Isaacs C.
PY  - 2026
JO  - Breast Cancer Res Treat
DO  - 10.1007/s10549-026-08011-6
UR  - https://doi.org/10.1007/s10549-026-08011-6
ER  - 

APA

F, L., M, R., L, L., M, M., X, X., & C., I. (2026). Real-world clinical outcomes of patients with early-stage TNBC and BRCAm who were treated with adjuvant capecitabine in the United States.. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-026-08011-6

Source records